NCT06837623View on ClinicalTrials.gov

Role of Colchicine as Anti-Inflammatory Therapy in HFpEF

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

February 22, 2025

Study Completion Date

March 1, 2025

Conditions

HFpEF - Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

Colchicine Tablets

"Oral colchicine tablets. The dosing regimen is as follows:~* Patients weighing \>70 kg: 0.5 mg twice daily (BID)~* Patients weighing ≤70 kg: 0.5 mg once daily (OD) Administered for 3 months"

Trial Locations (1)

11562

Cairo University - Kasr Al-Ainy, Cairo

All Listed Sponsors

lead

Cairo University

OTHER

NCT06837623 - Role of Colchicine as Anti-Inflammatory Therapy in HFpEF | Biotech Hunter | Biotech Hunter